Category Archives: Regenerative Medicine

ByDanny Jacobs

Two faculty teams with members affiliated with the Johns Hopkins Whiting School of Engineering have received grants for their research through the Cohen Translational Engineering Fund.

The fund, made possible by a generous commitment from Sherry and Neil Cohen '83, serves as a catalyst for translating cutting-edge research into practice by providing faculty with critical early funding. The grant is designed to help researchers move their work out of the laboratory and toward commercializationthe process includes developing patents, obtaining materials and supplies, and building prototypes.

"We are pleased to continue helping Whiting School of Engineering faculty advance their cutting-edge research," says Neil Cohen, who is also the founder of venture capital firm Emerald Development Managers. "Previous grantees are already realizing promising developments in their work, and we look forward to seeing this year's grantees further strengthen the pipeline of innovation and entrepreneurship coming out of the Whiting School of Engineering and Johns Hopkins."

Grantees receive a maximum of $100,000 for a nine-month project. Since its inception eight years ago, the Cohen Fund has awarded more than $1.3 million for 28 projects. Among the past recipients are LifeSprout, a regenerative medicine company; Ready Robotics, creator of operating software for industrial automation; Galen Robotics, which is developing steady-hand surgical robots; and Vectech, which is developing a surveillance system of cloud-connected smart mosquito traps.

A panel of experienced researchers, engineers, startup entrepreneurs, and business executives reviewed presentations from the five faculty finalists for this year's award in March.

"This year's recipients reflect the wide breadth of research done at the Whiting School and the key role that many Whiting faculty members play in cross-school collaborations," says Brian Stansky, senior director of FastForward. "Once again, the generous funding provided by Sherry and Neil Cohen will help multiple faculty members meaningfully move their academic research toward commercialization. We look forward to working with both recipient teams over the course of these projects and beyond."

The grantees are detailed below.

Principal investigator: Mark Foster, associate professor, Department of Electrical and Computer Engineering

The pitch: Monitoring 3D laser printing in real time to save manufacturers time and money

Laser powder bed fusion, or LPBF, is a 3D-printing process that uses high-powered lasers to rapidly melt and solidify metal powder into 3D objects such as heat sinks (which move heat away from a hot device) and jet fuel nozzles. The process, known as additive manufacturing, often leads to microscopic, random defects in the object, costing manufacturers time and money to replace parts.

Image caption: Mark Foster

Foster, working with Milad Alemohammad, a postdoctoral fellow, and Steven Storck, a senior materials scientist at the Johns Hopkins University Applied Physics Laboratory, has created novel, high-speed spectroscopic sensors that can be integrated into LPBF printing machines and provide real-time data so operators can correct defective layers as the object is being made.

The team developed the sensor at the request of collaborators at JHU APL's additive manufacturing center. They have received $250,000 in seed funding sponsored by the Army Research Laboratory and enabled by the MEDE+ AI-M program at the Hopkins Extreme Materials Institute, and they have taken part in the National Science Foundation's I-Corps program through Johns Hopkins Technology Ventures.

The team plans to use the funding to continue to refine its sensors as well as develop a user dashboard.

Principal investigators: Danielle Gottlieb Sen, director of pediatric cardiac surgery at Johns Hopkins Medicine and Youseph Yazdi, assistant professor of biomedical engineering and executive director of the Center for Bioengineering Innovation and Design

The pitch: Detecting a potentially deadly disease in infants and premature babies before symptoms appear

Image caption: Danielle Gottlieb Sen

Necrotizing enterocolitis, or NEC, is an often-fatal intestinal disease that disproportionately affects infants with congenital heart disease as well as premature babies. Treatment of NEC is most effective when started early, but currently, a diagnosis is confirmed only after symptoms appear, at which point substantial damage may already have occurred. Treatment can involve extended hospital stays or surgeries, and NEC can cause lifelong complications.

Image caption: Youseph Yazdi

Gottlieb Sen and Yazdi, working with Ellen Roche, on faculty at the Institute for Medical Engineering & Science at the Massachusetts Institute of Technology, are developing a noninvasive device that goes on a baby's belly to monitor intestinal ischemia, inadequate blood flow that is a known biomarker of the onset of NEC. The device, which will connect to bedside monitors, uses near-infrared spectroscopy, or NIRS, sensors to continuously record, store, and transmit data.

The team is building NIRS sensors that account for differences in pediatric patient size, and they are mapping pediatric intestine and vascular beds to ensure monitoring specificity. Their work could serve as a platform to develop accurate NIRS sensors for others tissues and diseases.

The team plans to use the funding to build the device as well as obtain results to start the process of receiving device approval from the U.S. Food and Drug Administration.

See the original post:
Meet the newest grantees of the Cohen Translational Engineering Fund - The Hub at Johns Hopkins

Wilmington, Delaware, United States: Additive manufacturing or 3D printing is witnessing innovations left, right and center. In various industries such as education, manufacturing, engineering, and medical, the use is extensive. It is pertinent to note here that it is the printing of biomaterials such as cells, components etc. in three dimension and that while it is a new area, it has made notable advancement in the past few years.

Read Report Overview - https://www.transparencymarketresearch.com/3d-bioprinting-market.html

It is important to note here that basis the kind of material, approach of bioprinting changes. It also changes according to cell types, cell growth factors, and other complexities relating to living tissues. This happens because there is a need for process to be sensitive to differences in these cells.

The domain of 3D bioprinting comes into play in a number of disciplines. Some of these include cell biology, physics, biomaterial sciences, and engineering. And, this process can also be use by experts in these fields and researchers so a wide variety of tissue can be developed. Designing and sizing of bones, vascular grafts, multi-layered skin, cartilaginous structure, tracheal splints, and cardiac tissue. As 3D bioprinting is used widely in this field, market for the same will chart significant growth.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11657

Thus, it does not come as a surprise that as per a comprehensive market report brought out by Transparency Market Research (TMR), the global 3D bioprinting market is on a high growth trajectory over the forecast period of 2017 and 2025. The repost carries incisive insights on market dynamics and unravels trends and drivers that are shaping the landscape of the market over the coming years. Besides, it gives a peek into regional growth potential share, and opportunities, etc.

3D Bioprinting Market Key Trends and Drivers

Demand or high throughput models of tissue, used extensively in drug research and discovery processes, is all set to propel growth in the global bioprinting market. And, since pharmaceutical and biotechnology market are coextensive with 3D bioprinting, development in the former leads to growth in the latter. Here, it is worth noting that advanced drug screening is also adding to the growth curve of the global 3D bioprinting market in a positive manner.

Get COVID-19 Analysis on 3D Bioprinting Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=11657

Additionally, extensive use in regenerative therapies which includes transplantation and generation will also underpin notable growth in the market. And, the advancements in regenerative medicine is also supporting this growth curve over the forecast period.

3D Bioprinting Market Key Players

The global 3D bioprinting market is fragmented and key players in the landscape include TeVido BioDevices, Rainbow Biosciences, 3D Systems, Inc., regenHU, EnvisionTEC GmbH, Stratasys Ltd., nScrypt, Inc., Regenovo Biotechnology Co., GeSiM, and Aspect Biosystems Ltd. These are profiled in the report and provide insight into strategies deployed by each to maintain a prominent hold over the global 3D bioprinting market.

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=11657

3D Bioprinting Market Regional Analysis

The regional analysis of the report is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Europe and North America will account for a prominent share of the global bioprinting market. There is a high demand for 3D printing in advanced clinical applications in the region. It is important to talk here of the upscaling of research and development in biotechnology and pharmaceutical industry in a number of North American and European countries.

More Trending Reports by Transparency Market Research

Medical Waste Containers Market: https://www.transparencymarketresearch.com/medical-waste-containers-market.html

Pressure Relief Devices Market: https://www.transparencymarketresearch.com/pressure-relief-devices.html

Orthopedic Devices Market: https://www.transparencymarketresearch.com/orthopedic-devices-market.html

Dental Implants Market: https://www.transparencymarketresearch.com/dental-implants-market.html

Virus Purification Kits Market: https://www.transparencymarketresearch.com/virus-purification-kits-market.html

Hemoglobin A1c Testing Devices Market: https://www.transparencymarketresearch.com/hemoglobin-a1c-testing.html

Medical Image Analysis Software Market: https://www.transparencymarketresearch.com/medical-image-analysis-software-market.html

Extracorporeal Membrane Oxygenation Machine Market: https://www.transparencymarketresearch.com/extracorporeal-membrane-oxygenation-machine-market.html

About Us

Transparency Market Research is a global market research firm offering the latest market research reports and business consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

See original here:
3D Bioprinting Market: Rise in Prevalence of Regenerative Therapies to Drive the Global Market - BioSpace

Patients struggling with weight loss can look no further than the Doctors Clinic, and specifically the practice of Gerald Parker, DO.

For patients who have tried dieting but failed to lose weight and keep it off, its time to try something different. At Doctors Clinic in Amarillo, Texas, Gerald Parker, DO has been helping patients of all ages lose weight for over 39 years with personalized medical weight loss programs. If youre ready to commit to your health and finally get rid of your extra pounds, contact Doctors Clinic or make an appointment online today.

What do medical weight loss programs include?

Doctors Clinic has a unique approach to weight loss. The providers dont rely on fads or gimmicks they help you change your relationship with food so you can follow a sensible, delicious, and sustainable diet and incorporate safe, moderate exercise into your daily routine.

Health assessment

Your doctor provides an exam and testing to identify how much weight you need to lose and whether you have any conditions that will affect your weight loss journey. They also track your blood pressure and glucose and cholesterol levels so you can see more improvements than just the number on the scale.

Meal planning

Your doctor helps you create a nutritious meal plan using real food that you buy at the grocery store. They can help you adjust your diet to get through plateaus or add variation if you need it. They also teach you about macros, nutrients, and other details to consider when choosing food.

Motivation

Making changes is challenging, but Doctors Clinic is in your corner every day. You have regular appointments to check your progress and adjust your program as necessary. You have small goals to keep you motivated as you work toward your ideal weight. Trust the medical weight loss program your doctor believes in your success.

Dr. Parker has been a guest speaker at national physician meetings including those for physicians specializing in weight loss. His nearly four decades of providing expert guidance and personalized care to patients put him at the forefront of medical professionals with the acumen to ensure every patient meets their goal.

Doctors Clinic offers cutting-edge regenerative and integrative medicine therapies to address each patients individual needs. A holistic, patient-focused approach helps patients address issues ranging from allergies and pain to weight management, while also enhancing their overall health and well-being.

Doctors Clinic welcomes new patients who are ready to improve their quality of life with personalized care and work with a true wellness partner. Appointments are available by calling the practice or using the online scheduling tool.

About Doctors Clinic:

Doctors Clinic, in Amarillo, Texas, is a state-of-the-art practice providing comprehensive health services for adult patients and specializing in regenerative medicine. Gerald Parker, DO is an experienced and compassionate provider who is committed to helping patients look and feel their best. The practice is happy to help patients on their wellness journey, whether theyre looking to enhance their health or if they need support to recover from injuries or diseases quickly and safely.

Media ContactCompany Name: Doctors ClinicContact Person: Gerald ParkerEmail: Send EmailPhone: (806) 355-8263Country: United StatesWebsite: Doctorsclinicamarillo.com

View post:
Doctors Clinic welcomes new patients who are ready to improve their quality of life - Digital Journal

ReportLinker

Report Scope: The report explains critical trends in the regenerative medicine industry. It discusses the market determinants, which act as motivating or restraining factors, and provides insights to stakeholders and potential entrants.

New York, June 20, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Regenerative Medicines: Bone and Joint Applications" - https://www.reportlinker.com/p0157460/?utm_source=GNW

This study looks at most of the systems affected by factors such as R&D spending and increasing competition and new technologies.

This report also covers merger and acquisition strategies and collaborations, as well as the strengths and weaknesses of each strategy type.

The market has also been analyzed based on regenerative medicine for bone and joint applications. Categories considered in this report include allogeneic bones, autogenic bones, bone graft substitutes, osteoarticular diseases and others.

The report provides information to all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding their geographic reach will also find this study useful.

Report Includes:- 51 tables- An overview of the global market for regenerative medicines for bone and joint applications- Estimation of the market size and analyses of global market trends, with data from 2020 to 2021, estimates for 2022, with projections of compound annual growth rates (CAGRs) through 2027- Characterization and quantification of market potential for regenerative medicines by technology, application, and region- Coverage and discussion on regulatory delays due to COVID-19, clinical trials and product launches of the industry- Description of principle approaches to regenerative medicine and discussion on importance of scaffolding in tissue engineering- Information on major drivers and regional dynamics of the market and current trends within the industry- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships and other key market strategies- Company profiles of major players, including Anika Therapeutics, Conmed Corp., Johnson & Johnson and Stryker Corp.

Summary:The global market for regenerative medicine for bone and joint applications was valued at REDACTED in 2021.By technology, this market is segmented into biomaterials, stem cell therapy and tissue engineering.

The tissue engineering segment recorded REDACTED revenue in 2021 and is expected to grow at a compound annual growth rate (CAGR) of REDACTED during the forecast period. The rapid growth rate of the tissue engineering segment is attributed to rising adoption of products that are designed and developed for the treatment of tissues such as bone, skeletal muscle, cartilage, blood vessel, nervetissue, skin and for complete organs.

Reasons for Doing This Study:The purpose of this report is to provide a summary of regenerative medicine products for the treatment of diseases and disorders of the bones and joints.Regenerative therapies have the potential to progress medical outcomes, improve quality of life and decrease overall healthcare costs.

A major objective is the utilization of living cells to repair or replace body tissue damaged by injury, disorder or the aging process.The most successful products draw upon multidisciplinary fields such as biology, medicine, engineering and, particularly, biomedical engineering.

This report is designed to be a critical decisionmaking tool for the intended audience, which includes biopharmaceutical market players, potential market entrants and other professionals involved with or interested in cell and gene therapy and regenerative therapy in orthopedic sector.Read the full report: https://www.reportlinker.com/p0157460/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

See original here:
Regenerative Medicines: Bone and Joint Applications - Yahoo Finance

Kangstem Biotech said Monday that it has voluntarily withdrawn a phase 1 and 2a clinical trial investigational new drug (IND) approval for "FURESTEM-OA Kit Inj.," a candidate material for stem cell-based osteoarthritis (OA) treatment.

The company decided to withdraw its plans after determining that it required further data reinforcement concerning establishing a cell bank for clinical trial drugs after the government started enforcing the "Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety and Support Act."

The Ministry of Food and Drug Safety had requested the results of the adventitious virus-negative test from Kangstem Biotech. The test proves that even when the test drug used in clinical trials is manufactured using a cell bank, the quality and safety are the same, and there is no scientific risk factor.

Accordingly, the company confirmed that there is no adventitious virus by completing the virus test by the qPCR test method following the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) regulations at Korean institutions.

Also, the company entrusted the test to the additional culture method of Charles River, an American consignment testing institution.

However, the company decided to voluntarily withdraw its IND approval, confirming it would be difficult to complete the test and analysis to secure additional data within the administrative processing period required for review of the clinical trial plan approval period.

"The IND application for the FURESTEM-OA Kit was for the first clinical trial for a stem cell-based fusion drug under the Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety and Support Act," Kangstems Clinical Development Division Director Bae Yo-han said. "Therefore, the IND approval process was somewhat delayed as the Ministry of Food and Drug Safety had to review its safety from various angles thoroughly."

During the delay period, additional test data that did not need to be initially submitted became a requirement, Bae added.

However, Bae stressed that the Ministry of Food and Drug Safety also believes that there are no additional problems in the clinical trial plan itself, other than a review on securing safety related to adventitious factors by ingredients used in the manufacturing process of the drug.

"Therefore, the company is aiming to re-apply for the phase 1 and 2a IND of the FURESTEM-OA Kit in July at the earliest and get approval within October," he said.

Due to the company's explanation, the company's shares rebounded on Wednesday after dropping about 5 percent the previous day.

As of 1:40 p.m. Tuesday, the company's stock price stood at 2,860 won ($2.22) per share, up 2.33 percent from the previous trading day.

Continued here:
Kangstem Biotech withdraws trial application for stem cell-based osteoarthritis treatment - KBR

Published 06-16-22

Submitted by Rockwell Automation

In an important step toward integrating biomanufacturing science with production techniques, Rockwell Automation (NYSE: ROK) announced the openingof the Rockwell Experience Center at the Advanced Regenerative Manufacturing Institute (ARMI) in Manchester, N.H. on June 8.

The new center will help teach ARMIs members, including physicians and researchers, how to leverage smart manufacturing to scale regenerative medicine products so they can be delivered to more people faster. ARMI's process relies on smart automation to help to mass produce safe and reliable biological products such as human tissues, skin, cartilage, and replacement organs. The center includes equipment from Rockwell, Air Science, Cytiva, Festo, and HID Global.

To say that the addition of the Rockwell Experience Center at the ARMI|BioFabUSA facility will be impactful to the area of regenerative medicine would be an understatement, said inventor, FIRST Robotics Founder and ARMI Executive Director Dean Kamen. By opening this center, we are able to demonstrate the baseline tools by which different types of human tissues and organs can be manufactured at scale. It's life changing.

Learn more about how ARMI and Rockwell are helping scientists create replacement tissues and organs. Watch this video and read this story.

About Rockwell Automation

Rockwell Automation, Inc.(NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 25,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visitwww.rockwellautomation.com.

More from Rockwell Automation

See the original post here:
Using Smart Manufacturing Technology to Scale Regenerative M - CSRwire.com

A battered woman. A wounded warrior. An injured football player.

All may come from different worlds. Yet, they may all be connected by one thing traumatic brain injury.

In the United States, traumatic brain injury, or TBI, affects approximately 1.7 million people. Most injuries occur in adolescents 15-19 and in older adults 65 and older. In 2020, more than 64,000 TBI-related deaths were reported in the country.

Across the globe, hundreds of researchers have dedicated careers to studying and testing methods to improve treatment options for TBI survivors. Michael Detamore, a biomedical engineering researcher at the University of Oklahoma, was recently awarded $640,000 from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health to fund his project: Single stage surgical intervention for treatment of severe traumatic brain injury.

According to a release, patients who suffer a severe TBI must undergo two surgeries one to remove a part of the skull to allow the brain to swell and another surgery to replace the missing bone after brain swelling subsides.

Detamore and his team may have found a way to reduce the number of surgeries to just one, which could be a very big deal.

When a doctor does a hemicraniectomy, removing the top part of the skull, there must be a second surgery, Detamore said. In a second surgery, they can either put back in a printed or metal plate or the original bone if it was preserved. But there is always a second surgery to fill that gap.

Traumatic brain injurys after-effects memory loss, dizziness, and depression can occur until the missing bone is replaced in a second surgery. Detamore believes patients can be treated through a single-stage surgical procedure using hydrogel materials.

The key to our approach is a new class of hydrogel materials, where natural materials including demineralized bone matrix, devitalized cartilage or devitalized tendon are themselves the crosslinkers of the hydrogel, Detamore said. Our material consists of a paste-like precursor solution of tissue particles and hyaluronic acid that behaves as a paste that a surgeon can easily sculpt into the open calvarial defect area. The material remains flexible so the brain can swell, and then be replaced by regenerating bone, eliminating the need for the second surgery.

Hydrogel starts as paste, like toothpaste or peanut butter, that the surgeon can spread and contour into the defects of the brain. When a light is shone on the paste, it sets. Its not solid like wood, its like Jell-O. Its flexible, but its solid.

Detamore recognizes that hundreds of researchers are studying TBI through different lenses such as psychological and pharmacological.

OUs research is unprecedented though, he said.

Our team is the first to use regenerative medicine as a tool to help treat traumatic brain injury.

Detamores interest in the field started about 15 years ago when he served on a masters thesis committee where a students work focused on paste-like biomaterials.

I remember thinking that the students research would be perfect for bone regeneration and it sounded like I was joking, but I was very serious and followed up on it, he said. That effort led to an NIH grant with Cory Berkland, of the University of Kansas, as principal investigator.

Flash forward to present day and Detamore is a principal investigator of this current NIH project. Berkland, Dr. Brian Andrews, a surgeon who specializes in head and neck surgery at the University of Iowa Hospitals and Clinics, and neuroscientist and the other principal investigator Randolph Nudo, University of Kansas Medical Center, also are involved in the initiative.

Current TBI surgical management hasnt changed much since the injury was first identified in 1908.

This means that unlike almost every other medical condition, there have been few to no advances to treat TBI, which is a debilitating and prevalent problem in our society. Moreover, there are few non-surgical options such as systemic drug therapy to treat TBI, Andrews said.

He wants his work to fill the gaps.

Today, the research team has eight key personnel.

OU is doing more of the work on the material side and the group at the University of Kansas are doing more of the work with the traumatic brain injury model. Neither university could do this project on its own, he said. Its the synergistic combination that makes this project possible and that is also what makes that unique niche possible. We are the only ones in the world doing this because of the different types of people coming together.

In 2016, Detamore was hired to lead the newly formed Stephenson School of Biomedical Engineering in the Gallogly College of Engineering at OU. He and then-student Jakob Townsend, continued to move the TBI research project forward. Townsend has since graduated from OU and continues to contribute to the project emphasizing that TBI affects more than just military personnel and athletes. It affects kids.

We need something that can be implanted into a child and grow with the child over time, he said. Hydrogel materials can accomplish that. When we talk with surgeons, we continue to learn of even more areas where hydrogels can make an impact and help patients. Each member of the team looks forward to seeing how far this project can go.

Read this article:
OU researcher works to transform care for traumatic brain injury - Journal Record

ReportLinker

Global Nanomedicine Market, By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes), By Nanoparticle Type (Polymer-based, Lipid-based, Nanocrystals, Inorganic, Others), By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others) By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others), By Region and Competition Forecast & Opportunities, 2027

New York, June 20, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nanomedicine Market, By Nanomolecule Type, By Nanoparticle Type, By Application By Disease Indication, By Region and Competition Forecast & Opportunities, 2027" - https://www.reportlinker.com/p06287479/?utm_source=GNW

The global nanomedicine market is expected to grow at an impressive CAGR of 8.28% in the forecast period, 2023-2027, to reach USD242655.19 million by 2027. The market is driven by the factors such as the growing healthcare expenditure and increased demand for personalized medicines. The massive prevalence of chronic and lifestyle disorders such as cancer and cardiovascular diseases across the globe is accelerating the application of nanomedicine in various healthcare applications. Also, the high-end investments in research and development activities by public and private players to find novel solutions for drug delivery and increase the effectiveness of drugs are expected to create lucrative growth opportunities for the global nanomedicine market in the forecast period.Nanomedicines are considered very effective in treating chronic diseases such as cancer, dementia, and diabetes as they fuel the metabolism of medications in the body.They deliver the drugs at the target site in the right proportion.

The markets availability of nanomedical products such as DNA probes, nanosensors, and nanoparticle-based imaging agents is increasing the demand. However, the high cost associated with the nanomedicine manufacturing process and research and development activities may hinder the global nanomedicine market in the forecast period.The global nanomedicine market is divided into nano molecule type, nanoparticles type, application, disease indication, regional distribution, and competitive landscape.Based on application, the nanomedicine market is divided into drug delivery, vaccines, diagnostic imaging, regenerative medicine, and others.

Drug delivery applications dominated the market in 2021 and captured 30.23% of the overall market share. This segment is expected to maintain its dominance over the next five years. The rise in awareness about the benefits of nanomedicine in drug delivery applications and the increased prevalence of diseases drives the demand for nanomedicines for drug delivery applications.The major market players operating in the global nanomedicine market are Pfizer Inc., Janssen Pharmaceuticals, Sanofi S.A., Amgen Inc., Moderna, Inc., Novo Nordisk A/S, Genentech, Inc., Celgene Corporation, Vifor Pharma Group, Teva Pharmaceutical Industries Ltd., among others.

Years considered for this report:

Historical Years: 2017-2020Base Year: 2021Estimated Year: 2022Forecast Period: 2023-2027

Objective of the Study:

To analyze the historical growth and the market size of the global nanomedicine market from 2017 to 2021. To estimate and forecast the market size of the global nanomedicine market from 2023 to 2027 and growth rate until 2027. To classify and forecast the global nanomedicine market is divided into nanomolecule type, nanoparticles type, application, disease indication, regional distribution, and competitive landscape. To identify drivers and challenges for the global nanomedicine market. To examine competitive developments such as expansions, new product launches, mergers, and acquisitions, etc., in the global nanomedicine market. To conduct pricing analysis for the global nanomedicine market. To identify and analyze the profile of leading players operating in global nanomedicine market.The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of leading nanomedicine manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the nanomedicine manufacturers who could not be identified due to the limitations of secondary research. The analyst examined the nanomedicine manufacturers, distribution channels and presence of all major players operating in the global nanomedicine market all over the world.The analyst calculated the global nanomedicine market size using a bottom-up approach, where data for various regions was recorded and forecasted for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Nanomedicine manufacturers/ suppliers/ distributors Government bodies such as regulating authorities and policy makers Organizations, forums, and alliances related to nanomedicine Market research and consulting firmsThe study is useful in providing answers to several critical questions that are important for industry stakeholders such as nanomedicine manufacturers, suppliers, distributors, and other stakeholders. The report would enable the stakeholders in strategizing investments and capitalizing on emerging market opportunities.

Report Scope:

In this report, global nanomedicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below: Nanomedicine Market, By Nanomolecule Type:o Nanoparticleso Nanoshellso Nanodeviceso Nanotubes Nanomedicine Market, By Nanoparticles Type:o Polymer-basedo Lipid-basedo Nanocrystalso Inorganico Others Nanomedicine Market, By Application:o Drug Deliveryo Vaccineso Diagnostic Imagingo Regenerative Medicineo Others Nanomedicine Market, By Disease Indication:o Oncological Diseaseso Infectious Diseaseso Orthopedic Disorderso Cardiovascular Diseaseso Others Nanomedicine Market, By Region:o North AmericaUnited StatesCanadaMexicoo EuropeGermanyFranceUnited KingdomItalySpainDenmarko Asia PacificChinaJapanIndiaAustraliaSouth KoreaMalaysiaVietnamo South AmericaBrazilArgentinaColombiao Middle East & AfricaTurkeyIsraelSouth AfricaSaudi ArabiaUAEKuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global nanomedicine market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).Read the full report: https://www.reportlinker.com/p06287479/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Go here to read the rest:
Global Nanomedicine Market, By Nanomolecule Type, By Nanoparticle Type, By Application By Disease Indication, By Region and Competition Forecast &...

Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited.

Cardiologist Dr. Joshua Hare is one of those scientists, and hes both the co-founder and chief scientific officer of Longeveron Inc. LGVN, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Hes also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.

The global regenerative medicine market is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019.

Hare recently spoke at a TEDx Miami conference on aging and the advancements his team is making toward slowing down and possibly reversing the aging process.

Too often when people age, they become frail and disabled, reducing the quality of life for those who live well into their golden years, Hare said. He said prolonging a persons life without restoring their health really isnt living at all.

He opens his talk by discussing life in the 1880s and how people only lived to be in their 40s. He discussed how childbirth could be a death sentence for many and how the discovery of germ theory led to more successful pregnancies and childbirth as the human lifespan doubled over time.

He likens this discovery to regenerative medicine and how harvesting human stem cells can be used as medicine in the future.

Around the world, top medical scientists are studying the biology of aging, just as scientists in 1880 were trying to understand the biology of bacteria, Hare said.

He explained how medical scientists are studying changes that occur during the aging process and how the entire body is affected from the changes in blood vessels to a weakened immune system and ones outward appearance.

He explains that reservoirs made of stem cells improve the health of vital organs and allow tissues to heal by replacing dying cells that are slowly diminishing. He poses the following questions:

Almost eight years ago, Hare started Longeveron and began testing stem cells as one of many treatments to find a possible fountain of youth.

When we think about aging, it's not just the longevity of life, Hare said. It's not just how long we live. But it's also the quality of those years as human lifespan has increased. Unfortunately, the period of time where we're disabled at the end of our life has also increased.

Anti-aging treatments should not be focused on the length of human life but rather on the quality of human life, Hare said, noting that people around the world are at risk of frailty, chronic disease and poor health as they age.

Longeveron says its on a mission to create a paradigm shift in science and medicine, developing therapies derived from culture-expanded and isolated medicinal signaling cells (MSCs) extracted from the donated bone marrow of healthy young adults.

Grown in a laboratory, these multipotent MSCs reportedly have unique therapeutic properties, including homing to inflammation and tissue damage sites. By stimulating these cells, its sometimes possible to maintain organ health, repair deteriorating tissues and restore immune function.

The companys website explains this phenomenon:

As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation and other issues. Our clinical data suggest that Lomecel-B addresses these conditions through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes.

Longeverons current areas of research focus include:

Hare explained how CAR T-cell therapy can kill cancer and said he is ready to lead the new frontier in developing safe and effective cell therapies for some of the most challenging diseases and conditions associated with aging.

Companies like Statera Biopharma Inc. STAB, Concert Pharmaceuticals CNCE, Annovis Bio ANVS, Cassava Sciences SAVA, and Lineage Cell Therapeutics Inc. LCTX might be right by his side.

To learn more about Longeveron and how its using allogeneic stem cells to attempt to create a host of therapies for healing and aging, check out https://www.longeveron.com.

Watch the TEDx Talk here: https://loom.ly/1xhSmBY

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Image by Mehmet Turgut Kirkgoz on Pixabay

Originally posted here:
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It - - Benzinga

Miami, FL, June 21, 2022 (GLOBE NEWSWIRE) -- Grand Havana, Inc. (OTC Pink: GHAV) (GHAV or the Company), is pleased to announce the signing of an agreement (Agreement) with Can B Corp, Inc. (OTCQB: CANB) (CANB), a health and wellness company specializing in developing, producing and selling hemp-derived cannabinoid products.

Under the terms of the Agreement, Havana will assist Can B in the research and development of a proprietary CBD additive (Additive) that Havana will add to their production process to allow the CBD to be infused in the coffee once brewed. The actual Additive manufacturing will be done in Can Bs Miami, Florida R&D lab and processing center or other production facilities as needed.

To expedite time to market, Havana intends to leverage its scalable network of manufacturing and distribution centers throughout Florida in addition to Can B commitment to add the CBD Coffee to its product offerings. The new CBD infused coffee will be available in Havanas optimum blend medium dark roast in a 12-ounce double zipped bag with an air valve for freshness.

Furthermore, the company has signed a partnership agreement with Peter Michael MD MBA a certified specialist with the ability to provide medical marijuana card evaluations. Under the agreement, Dr. Peter Michael will be the face of the 12oz Grand Havana CBD Infused coffee.

Grand Havana is now taking pre-orders on our company website http://www.grandhavanacoffee.com

Tanya Bredemeier Chief Executive Officer of Grand Havana, Inc. commented, After numerous discussions and much consideration, the Company is happy to have finally found the right commercialization and brand development partner with Can B to bring CBD infused coffee product to fruition. Ms. Bredemeier further added We welcome Dr. Peter Michael onboard and look forward to branding our CBD coffee as the best products in the market we are using the Companys flagship dark roast Cuban style espresso brand, Grand Havana, will also be the first to offer CBD-infused espresso, which will be made available to consumers as soon as possible in our cafes and online. Havana currently services over 1,000 retailers in the southeast market and is looking to expand.

Marco Alfonsi, Can Bs Chief Executive Officer, stated, This is a significant expansion milestone for our company as coffee is still Americas favorite beverage and its popularity continues to grow. Added Mr. Alfonsi, the CBD opportunity with Havana is evidence of the growing market wide expansion into the CBD beverage opportunity and we are glad to be linked with Grand Havana, Inc.

Dr. Peter Michael states As a certified regenerative medicine and anti-aging specialist I have been using CBD to help my patients in a variety of ways. The CBD, produced by CANB Corp., blended with Grand Havana espresso delivers an effective combination of flavor, focus and energy. The product is designed to enhance alertness, relieve stress and provide energy through the synergistic effects of caffeine and CBD in dopamine and serotonin.

About Grand Havana, Inc.

Grand Havana is a coffee company headquartered in Miami, Florida The Capital of Espresso in the US.

Grand Havana products are distributed by Sysco, Ambassador Foods and Amazon. We proudly serve our coffees in corporate offices, airports, universities, non-traditional avenues, supermarkets, convenience stores, hotels, online marketplaces and in our fresh and exciting chain of Grand Havana Caf coffee shops across the US. With more than 10 million cups of coffee served nationwide, Grand Havana is the choice of consumers when it comes to delving into the nostalgia and essence of the best cup of Cuban coffee, thus offering a b2b solution that provides our high-quality coffee product delivered and reliable with timely technical service.

For more information, visitwww.Grandhavanacoffee.com, call 1.800.608.5441, or emailorders@grandhavanacoffee.comFind out more about the company atwww.Facebook.com/grandhavanacoffee,twitter.com/grandhavcoffee1, orwww.instagram.com/grandhavanacoffee/

About Can B Corp.

Can B Corp. (OTCQB: CANB) is a health & wellness company providing the highest quality hemp derived cannabinoid products, including under its own brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. CanB Corp. operates R&D and production facilities in Lacey, WA, and Florida. To learn more about Can B Corp. and our comprehensive line of high quality products, please visit: Canbiola.com andwww.CanBCorp.com, follow Can B Corp on Instagram and Facebook, or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: http://www.CanBCorp.com

About Dr. Peter Michael

Dr. Peter Michael is a certified specialist with the ability to provide medical marijuana card evaluations a graduate of the University of Miami Miller School of Medicine. He completed his internal medicine residency at Howard University Hospital and his physical medicine and rehabilitation (PM&R) at the University of Miami Miller School of Medicine. In 2016, he completed an interventional pain management fellowship at the Florida Spine Institute, and in 2017, a interventional pain and regenerative sports medicine fellowship with Marko Brodor MD.Dr. Michael additionally received his Master of Business Administration from University of Miami School of Business in 2011, and has been published in various journals and conferences.

Forward-Looking Statements

Forward-looking statements and risks and uncertainties discussed in this release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of latest information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Go here to see the original:
Grand Havana, Inc. Launches Grand Havana CBD Infused Coffee with Can B Corp, Inc. Adding Dr. Peter Michael as its Brand Ambassador to represent Grand...